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Abstract 
Coronary angioplasty (or percutaneous coronary 
intervention, PCI) is a mature and widely diffused 
treatment technique for coronary artery disease. Over the 
last decades, great evolution has been realized concerning 
the related technology, the pharmacologic armamentarium 
and operators’ experience resulting in improved safety and 
success rates of PCI.  Despite the fact that associated risks 
have declined over time, since PCIs are invasive 
procedures, complication rates have always been and still 
are a vexing reality. They concern the cardiologist who sets 
the indication, the interventionalist who performs the 
procedure but most importantly the patient who should be 
well informed for the anticipated benefits and risks before 
giving his written informed consent. A concise update on 
recent data about the most important issues regarding PCI 
complications is attempted herein.   
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Abbreviations: BARC = Bleeding Academic Research 
Consortium; CIN: contrast-induced nephropathy; NCDR = 
National Cardiovascular Data Registry; PCI = percutaneous 
coronary intervention; STEMI: ST-segment elevation 
myocardial infarction 
 
Introduction 
Any percutaneous coronary intervention (PCI) is a 
procedure with expected benefits but also with potential 
risks. As with any invasive procedure there should be a 
clear indication that justifies even the smallest possible  
risk.1 Procedural success and complication rates are used 
to measure outcomes after PCI. Procedural success is 
defined as angiographic success without the occurrence of 
major complications (death, myocardial infarction or 
cardiac surgery) within 30 days of the procedure. Clinical 
success is defined as procedural success without the need 
for urgent repeated PCI or surgical revascularization 
within the first 30 days of the procedure.2 Several clinical, 
angiographic, and technical variables predict the risk of 
procedural failure in patients undergoing PCI. Major 
complications include death, myocardial infarction and 
stroke, while minor complications include transient 
ischemic attacks, vascular complications, contrast-induced 
nephropathy (CIN) and some angiographic complications.2 
Substantial improvements in coronary devices, adjunctive 
antithrombotic therapy and secondary prevention after PCI 
have significantly improved early and late clinical 
outcomes after PCI over time.3 
Morbidity and mortality after PCI undoubtedly have 
been decreasing during the last two decades while minor 
incidents were probably underestimated.4, 5  However, 
complication rates remain vexing and vary among various 
recent reports, depending mainly on the characteristics of 
the population under study.  
 
Mortality 
Although mortality after PCI is generally rare (<1%), it 
depends on the clinical profile of each patient and thus 
mortality risk models have been previously developed to 
facilitate patient-level management (guiding therapeutic 
decisions and informed consent) but also to be applied for 
quality of care assessment and clinical research.  Data from 
the National Cardiovascular Data Registry (NCDR) have 
been used to develop and validate PCI risk models 
including a “full” model of 21 variables with angiographic 
details, a pre-catheterization model without angiographic 
details and most importantly a simplified bedside risk 
score of 8 variables.6 As has been indicated in the recently 
developed EuroHeart PCI score, in-hospital mortality 
among PCI patients can be well predicted by a risk 
estimation model that contains 16 variables.4 This is the 
most contemporary risk score available that has been 
validated in a large European population (two data sets of 
>20000 patients each) and where 3 clinical factors have 
been demonstrated as the strongest predictors of peri-
procedural mortality: age >80 years, hemodynamic 
instability and primary PCI for STEMI.4 Results from 
more than one million procedures included in the NCDR 
contributed to an updated CathPCI Registry mortality 
model that was reported recently.5 In-hospital mortality 
was 1.4%, ranging from 0.2% among elective cases to 
65.9% among patients with shock and recent cardiac arrest. 
Table 1 demonstrates in detail how the NCDR (initial and 
newest) risk scores and the EuroHeart PCI risk score are 
calculated and Table 2 the above respective scores that 
predict several in-hospital mortality levels. 
It might be more useful though to consider 
cardiovascular complications and importantly all-cause 
mortality early after PCI, extending at the post-discharge 
period, which by consensus is measured at 30 days after 
intervention. In the New York state PCI registry the overall 
complication rate was 3.36% with a mortality rate of 0.6% 
at one month and 0.047% in the catheterization 
laboratory.7 Cardiogenic shock and procedure urgency 
were the most predictive of inpatient mortality, whereas 
the presence of a chronic total occlusion, subacute stent 
thrombosis and left main lesion location were significant 
6 
 
angiographic predictors.5 Generally prognosis worsens 
with increasing clinical acuity: in-hospital mortality is 
higher in the setting of STEMI, in cardiogenic shock and 
in patients who develop an occlusion with prior poor left 
ventricular function, while patients of advanced aged and 
acute coronary syndromes are particularly vulnerable.2 
Data from the British Columbia Cardiac Registry have led 
to the identification of several risk factors for 30-day 
mortality prediction after PCI in order to construct a risk 
score model.8 In recent randomized controlled studies 
early mortality is low and for patients with stable angina it 
varies between 0.3 and 1%.9-12    
The evolution towards death after PCI is not necessarily 
of cardiac origin since the mechanisms that lead to major 
events are multiple and interrelated. In a recent report 
coming from a registry of >5000 patients, in-hospital 
mortality was found at 1.5%. Left ventricular failure was 
the most common cause of death (35.3%), followed by 
neurological compromise (16.5%) and arrhythmia 
(12.1%). Of note, procedural complications were 
responsible for a small fraction of deaths (7.1%) and 
reviewers determined 93% of deaths to be mostly or 
entirely unpreventable.13 
 
Myocardial infarction 
The most frequent mechanisms are the embolization of 
atherothrombotic fragments and the occlusion of side 
branches or collateral branches after stent implantation. 
The most serious complication is an occlusive coronary 
dissection with failure to cross for stent delivery.  
Myocardial infarction is probably the most imperfectly 
determined complication among PCI registries since 
definitions have been varying for the last two decades and 
comparison between studies would therefore be futile. 
According to the latest third universal definition of 
myocardial infarction the diagnosis of a myocardial 
infarction related to PCI (type 4a) is arbitrarily made in 
case of a rise of troponin more than five times above the 
upper 99th percentile of the normal values in patients with 
normal baseline values or a rise of troponin values more 
than 20% if the baseline values have been initially elevated 
and are stable or falling.14 In addition, either (i) symptoms 
suggestive of myocardial ischemia, or (ii) new ischemic 
ECG changes or new LBBB, or (iii) angiographic loss of 
patency of a major coronary artery or a side branch or 
persistent slow- or no-flow or embolization, or (iv) 
imaging demonstration of new loss of viable myocardium 
or new regional wall motion abnormality are required.14 
According to this latest definition a recent study reported 
rates of PCI related myocardial infarction around 4%, 
which seems a correct estimation.15 However it should be 
noted that a threshold for a worsening prognosis, related to 
an asymptomatic increase of cardiac biomarker values in 
the absence of procedural complications is not yet 
determined due to still unconvincing data.16, 17 
 
Stent thrombosis 
A subcategory of PCI-related myocardial infarction is 
stent thrombosis, as documented by angiography and/or at 
autopsy and a rise and/or fall of troponin values 
(myocardial infarction type 4b).14 According to the 
Academic Research Consortium recommendation the 
occurrence of stent thrombosis should be stratified in 
relation to the timing of the PCI procedure as “early” (0 to 
30 days), “late” (31 days to 1 year), and “very late” (>1 
year) to distinguish likely differences in the contribution of 
the various pathophysiological processes during each of 
these intervals.18Early stent thrombosis is very often 
related to technical PCI issues, such as imperfect stent 
deployment or residual dissection (example in Figure 1). 
Stent thrombosis risk remains high especially during the 
first 15 days following stent implantation having as 
predisposing risk factors a context of acute coronary 
syndrome (especially STEMI), premature antiplatelet 
treatment discontinuation and clopidogrel resistance 
(genetic or other).19 
The most potent available antiplatelet drugs - ticagrelor 
and prasugrel - have contributed in the reduction of acute 
stent thrombosis rates, which is estimated between 0.3% 
and 0.8% in recent studies.9-11 For the moment according 
to the guidelines they are preferentially used in acute 
coronary syndrome cases, while clopidogrel should be 
prescribed for elective PCI.20 
 
 
Figure 1. A subacute stent thrombosis case explained by 
technical issues regarding PCI. 1) A subocclusive, thrombotic 
lesion of a dominant circumflex artery at the level of the first 
marginal branch is the culprit lesion for a non ST-elevation acute 
coronary syndrome. The marginal branch has also significant 
ostial-proximal disease, 2) PCI was performed with direct 
stenting using a 3x15 mm stent and no bifurcation technique 
while the disease at the origin of the first marginal was not 
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addressed, 3) Stent thrombosis 5 days later, 4) PCI for stent 
thrombosis with only thromboaspiration (10 runs) and 
adjunctive abciximab intracoronary bolus and IV infusion with 
restoration of TIMI III flow but still visible residual thrombus 
fragments, 5) After 10 days of intensified dual antiplatelet 
(clopidogrel replaced by prasugrel) and antithrombotic therapy 
there is no angiographic thrombus. With optical coherence 
tomography a small proximal residual thrombus is discovered 
and the stent is found underexpanded and undersized (3mm stent 
for a 3.5 mm artery diameter), 6) Final result after PCI for the 
circumflex stent optimization and additional stenting for the 
marginal ostium-proximal disease using a bifurcation technique. 
 
Coronary perforation 
It is a very rare but life-threatening complication with 
an incidence that is not well determined. In a study of more 
than 7000 procedures the incidence of perforation was 
0.93% and almost two thirds of them occurred during PCI 
for chronic total occlusion.21 The two possible mechanisms 
are well identified: 
- Coronary artery rupture, usually upon lesions calcified 
and resistant. It can be caused by oversized balloons or 
stents, balloon rupture, aggressive stent post-dilatation or 
excessive rotablation.   
- Distal perforation, usually in cases of chronic occlusions 
and/or severe coronary tortuosity. It is caused by guidewire 
exit, especially with the use of stiff and hydrophilic 
guidewires.  
Both mechanisms can lead to rapidly accumulating 
pericardial effusion with cardiac tamponade and require 
emergency pericardiocentesis. The most important 
countermeasures are graft stents in case of coronary 
rupture and distal embolization with various interventional 
radiology techniques (usually with thrombogenic coils) in 
case of distal perforation. Necessary material should be 
readily available in the catheterization laboratory.  
Emergency cardiac surgery is the ultimate solution in case 
of failure of the above. 
 
Emergency cardiac surgery 
The need for emergency surgery to bail-out a 
complication has decreased dramatically over the years 
and it is quite rare nowadays, in 0.61% of PCI procedures 
according to a recent report from a large US registry 
(>18000 procedures, between 1992 and 2000).22 It is 
indicated mainly for an extensive coronary dissection 
(61%), perforation/tamponade (20%) or a recurrent 
coronary artery occlusion (20%). In even rarer cases (1-
2%) it may be needed because of iatrogenic aortic 
dissection or the impossibility to retrieve devices and 
material used during PCI.22 
 
Cerebrovascular accident 
Stroke is a rare but possibly dramatic complication of 
PCI because of functional consequences. In the PCI 
Registry of the Euro Heart Survey periprocedural stroke 
was observed in 0.4% of all PCI procedures, in 0.3% of 
PCIs in elective patients and in 0.6% in PCIs performed 
for ACS. The overall in-hospital mortality was 19.2% for 
patients who developed stroke compared with 1.3% for 
those without stroke. Hemodynamic instability, age ≥ 75 
years, history of stroke, and congestive heart failure were 
found to be independent predictors for periprocedural 
stroke in acute coronary syndromes, whereas only PCI of 
a bypass graft and renal failure could be identified as 
independent predictors in elective patients. That means 
that most predictors for periprocedural stroke are not 
modifiable and cannot be diminished before PCI.23 This 
makes sense since catheter manipulation is inevitable 
while at the same time risk factors for coronary, 
cerebrovascular and aortic atherosclerotic disease overlap.  
 
Hemorrhagic complications 
They are divided in two categories according to their 
timing. 
Immediate, in-hospital hemorrhagic complications. 
They largely depend on the arterial access site, since the 
radial approach reduces by 50% major hemorrhagic 
complications, especially in acute coronary syndromes. 
The radial approach reduces bleeding complications 
and is especially advantageous in certain patient subgroups 
(those with obesity, anticoagulation, haemostasis 
disorders, chronic pulmonary disease).24 Moreover, the 
results from the recently reported RIVAL study did not 
demonstrate a mortality advantage for an all-comer radial 
approach among patients undergoing PCI, except for the 
primary PCI subgroup which did demonstrate a mortality 
benefit.25  This is why in the latest European myocardial 
revascularization guidelines the radial approach holds a 
class IIa indication for primary PCI provided that it is 
performed by an experienced radial operator.20 
The other half of major bleeding complications is not 
related to the access site and is associated with 3 times 
higher 1-year mortality when the Bleeding Academic 
Research Consortium (BARC) universal classification is 
applied.26 The causal relationship as a mechanism linking 
major bleeding complications and mortality remains for 
the moment elusive. 
Late hemorrhagic complications. They are 
underreported because they appear after hospitalization. 
They are related to oral anticoagulants and the more potent 
antiplatelet agents. According to current data and 
guidelines only clopidogrel, but not the more potent 
ticagrelor or prasugrel, should be used when a triple 
association of a vitamin K antagonist, aspirin and a P2Y12 
inhibitor is indicated after stenting for patients with atrial 
fibrillation or other indication for chronic oral 
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anticoagulation, which makes sense considering the 
bleeding risk.20 The abovementioned triple association 
should be of the most limited period possible since it 
doubles major bleeding events rates that are related to 
increased mortality.27, 28 Actually some emerging data 
support the discontinuation of clopidogrel at three months 
after newer generation DES implantation for patients with 
stable coronary artery disease or low-risk acute coronary 
syndrome.10 
 
Vascular access site complications 
Regarding the femoral approach one should have in 
mind the most dreaded complication which is the 
retroperitoneal hemorrhage. Recently reported data from a 
large registry (>110000 patients) inform us that 
retroperitoneal hemorrhage is rare (0.4%) after PCI. It is 
usually related to high femoral puncture but it can occur 
even with an ideal puncture site due to movement of blood 
along fascial planes. The vast majority is treated medically 
(>90%) but there is significant mortality (6-7%) associated 
with this complication.29 The other two important femoral 
access complications that sometimes need to be treated by 
vascular surgery, are the pseudoaneurysm and the 
arteriovenous fistula. Ischemic complications such as 
arterial dissection, thrombosis or distal embolism are also 
possible but rare and related to preexisting peripheral 
arterial disease. The predictive factors of femoral access 
related complications are female gender, advanced age, 
very low body surface area, diabetes mellitus and 
anticoagulant treatment.  
The radial approach has been gaining popularity among 
interventionalists since it is practically free of the above 
complications and furthermore the risk of significant 
hematoma is very low. The most frequent radial access 
related complication is radial artery thrombotic occlusion 
(3-5% at 30 days) which is usually clinically silent. Such 
advantages have led to an increasing adoption of the 
technique by interventional cardiologists. According to a 
recent report from the NCDR the proportion of transradial 
PCI procedures has increased from 1.2% in 2007 to 16.1% 
in 2012 and accounted for 6.3% of total procedures from 
2007 to 2012.30 
 
Contrast-induced nephropathy 
 
Contrast-induced nephropathy (CIN) is a common 
complication among patients undergoing PCI and is 
related to increased morbidity, mortality, and healthcare 
costs. Several efforts have been made to develop risk 
prediction tools to identify patients most likely to develop 
CIN. The most commonly used risk score was described 
by Mehran et al. and is based on the presence of 8 factors 
which are mainly pre-procedural but also two procedural 
(hypotension, use of intra-aortic balloon pump, congestive 
heart failure, chronic kidney disease, diabetes, age >75 
years, anemia and volume of contrast).31 A novel risk 
prediction algorithm including only pre-procedural clinical 
and laboratory variables has been recently developed and 
proposed to calculate the risk of CIN (and new requirement 
for dialysis) among patients undergoing PCI.32 This risk 
score may prove useful for clinical decision making as well 
as quality of care assessment, and can be reliably 
calculated at bedside and before the procedure using a 
novel easy-to-use computational tool available online 
(https://bmc2.org/calculators/cin) and in a smartphone 
application (named SCAI PCI Risk Calculator). 
Multiple strategies have been demonstrated to be 
successful for prophylaxis of CIN and are recommended 
in the latest European revascularization guidelines, 
including adequate hydration with isotonic saline (class I-
A) and the use of iso-osmolar or certain low osmolar 
contrast media with minimization of contrast dose at 
<350ml or <4ml/kg or total contrast volume/glomerular 
filtration ratio <3.4 (class I-A).20  The implementation of 
high-dose statin before catheterization has been shown to 
reduce the incidence of CIN and should be considered as 
an additional preventive measure in patients without 
contraindications (class IIa-A).20, 33 Of note, the 
effectiveness of other pharmacological preventive 
measures such as N-acetylcysteine, sodium bicarbonate 
0.84% infusion (class III-A for both) or prophylactic pre-
procedural hemodialysis -remains unproven (class III-B).20 
 
Preparedness for complications 
Mortality related to PCI complications is low and is 
practically unchanged for the last decade. Despite the 
improvement of techniques and devices this could be 
explained by the parallel increasing complexity of cases 
that are attempted. Patients should be well informed for the 
benefits and risks of each procedure and give written 
informed consent. Each operator should acknowledge his 
limits, evaluate the risks, anticipate technical difficulties 
and plan every single intervention accordingly. The 
catheterization laboratory should have all the necessary 
equipment (i.e. graft stents, coils, pericardiocentesis kit, 
etc.) readily available to confront any possible 
complication. All the above are necessary in order to be 
able to prevent complications and save the day when they 
arrive. 
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Table 1.  NCDR and EuroHeart PCI risk scores for in-hospital mortality. 
 
NCDR PCI score6 NCDR PCI score (newest)5 EuroHeart PCI score4
Variable Points Variable Points Variable Points 
Age 
<60 
60-69 
70-79 
≥80 
 
0 
4 
8 
14 
Age 
<60 
60-69 
70-79 
≥80
 
0 
4 
9 
15
Age 
<60 
60-69 
70-79 
≥80
 
0 
2 
3 
6 
Cardiogenic shock* 25 STEMI* 6 Valvular heart disease* 2 
Prior CHF* 5 CVD* 2 Prior stroke* 2 
PAD* 5 PAD* 3 Female gender* 2 
Chronic lung disease*  4 Chronic lung disease* 3 Ever smoker* 1 
GFR 
<30 
30-60 
60-90 
>90 
 
18 
10 
6 
0 
GFR 
<30 
30-45 
45-60 
60-90 
>90
 
16 
11 
7 
3 
0 
CAD severity 
Left main disease 
3-vessel disease 
Proximal LAD disease 
Bifurcation lesion 
Type-C lesion 
 
3 
1 
2 
2 
2 
 
NYHA class IV* 
 
 
4 
NYHA class within 2 weeks 
NYHA IV 
NYHA <IV 
No heart failure 
 
7 
3 
0 
  
 
PCI status (STEMI) 
Elective  
Urgent 
Emergent 
Salvage 
 
 
12 
15 
20 
38 
CS/PCI status 
Sustained shock and salvage 
Sustained shock or salvage 
Transient shock, no salvage 
Urgent (no shock/salvage) 
Emergent (no shock/salvage) 
Elective (no shock/salvage) 
 
54 
43 
37 
22 
11 
0 
 
PCI indication 
Ongoing STE-ACS 
Ongoing non STE-ACS 
Stabilized after ACS 
 
 
8 
6 
4 
 
PCI status (no STEMI) 
Elective  
Urgent 
Emergent 
Salvage 
 
 
0 
8 
20 
42 
LVEF 
<30 
30-39 
40-49 
≥50 
 
9 
4 
2 
0 
 
Hemodynamic instability 
Yes 
No 
 
 
11 
0 
  Prior PCI* 3  
No prior CABG* 
 
4 
  Cardiac arrest (<24 hours)* 13 TIMI flow 0/1 before PCI* 2 
  Diabetes mellitus 
Insulin 
No insulin 
No 
 
3 
2 
0 
 
Diabetes mellitus 
Yes 
No
 
 
3 
0 
  BMI (kg/m2) 
<20 
20-29 
30-39 
≥40 
 
5 
1 
0 
3 
 
BMI (kg/m2) 
<25 
≥25 
 
 
2 
0 
 
STEMI, ST-elevation myocardial infarction; CHF, congestive heart failure; CVD, cardiovascular disease, PAD, peripheral arterial disease, GFR, glomerular filtration ratio; 
CAD, coronary artery disease; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass grafting; BMI, body mass 
index.   *No points (0) if characteristic not present. 
 
Table 2. NCDR and EuroHeart PCI respective scores 
that predict certain in-hospital mortality levels. 
 
In-hospital 
mortality (%) 
NCDR PCI 
score6 
NCDR PCI 
score (newest)5 
EuroHeart PCI 
score4 
1 
3 
5 
10 
15 
20 
40 
>50 
29 
38 
43 
49 
53 
56 
64 
>68 
35 
47 
53 
61 
66 
69 
78 
>84 
14 
20 
24 
26 
28 
30 
33 
>35 
 
 
REFERENCES 
 
1. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. 
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness 
Criteria for Coronary Revascularization: a report by the ACCF 
Appropriateness Criteria Task Force, SCAI, STS, AATS, AHA, 
and the ASNC, Endorsed by the ASE, the HFS, and the SCCT. 
J Am Coll Cardiol 2009;53:530-553. 
2. Levine GN, Bates ER, Blankenship JC, et al. 2011 
ACCF/AHA/SCAI Guideline for PCI: executive summary: a 
report of the ACCF/AHA Task Force on Practice Guidelines and 
the SCAI. Catheter Cardiovasc Interv 2011;79:453-495. 
3. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 
patients undergoing percutaneous coronary intervention in the 
era of drug-eluting stents: report of the DEScover Registry. 
Circulation 2006;114:2154-2162. 
10 
 
4. de Mulder M, Gitt A, van Domburg R, et al. EuroHeart score 
for the evaluation of in-hospital mortality in patients undergoing 
PCI. Eur Heart J 2011;32:1398-1408. 
5. Brennan JM, Curtis JP, Dai D, et al. Enhanced mortality risk 
prediction with a focus on high-risk percutaneous coronary 
intervention: results from 1,208,137 procedures in the NCDR. 
JACC Cardiovasc Interv 2013;6:790-799. 
6. Peterson ED, Dai D, DeLong ER, et al. Contemporary 
mortality risk prediction for percutaneous coronary intervention: 
results from 588,398 procedures in the National Cardiovascular 
Data Registry. J Am Coll Cardiol 2010;55:1923-1932. 
7. Stathopoulos I, Jimenez M, Panagopoulos G, et al. The 
decline in PCI complication rate: 2003-2006 versus 1999-2002. 
Hellenic J Cardiol 2009;50:379-387. 
8. Hamburger JN, Walsh SJ, Khurana R, et al. PCI and 30-day 
mortality: the British Columbia PCI risk score. Catheter 
Cardiovasc Interv 2009;74:377-385. 
9. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet 
inhibition with cangrelor during PCI on ischemic events. N Engl 
J Med 2013;368:1303-1313. 
10. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months 
of dual antiplatelet therapy after zotarolimus-eluting stents: the 
OPTIMIZE randomized trial. JAMA 2013;310:2510-2522. 
11. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment 
with prasugrel in non-ST-segment elevation acute coronary 
syndromes. N Engl J Med 2013;369:999-1010. 
12. Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started 
during emergency transport for primary PCI. N Engl J Med 
2013;369:2207-2217. 
13. Valle JA, Smith DE, Booher AM, Menees DS, Gurm HS. 
Cause and circumstance of in-hospital mortality among patients 
undergoing contemporary PCI: a root-cause analysis. Circ 
Cardiovasc Qual Outcomes 2012;5:229-235. 
14. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal 
definition of myocardial infarction. J Am Coll Cardiol 
2012;60:1581-1598. 
15. Leonardi S, Truffa AA, Neely ML, et al. A novel approach 
to systematically implement the universal definition of 
myocardial infarction: insights from the CHAMPION 
PLATFORM trial. Heart 2013;99:1282-1287. 
16. Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes 
DR, Jr. Significance of periprocedural myonecrosis on outcomes 
after percutaneous coronary intervention: an analysis of 
preintervention and postintervention troponin T levels in 5487 
patients. Circ Cardiovasc Interv 2008;1:10-19. 
17. Lansky AJ, Stone GW. Periprocedural myocardial infarction: 
prevalence, prognosis, and prevention. Circ Cardiovasc Interv 
2010;3:602-610. 
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points 
in coronary stent trials: a case for standardized definitions. 
Circulation 2007;115:2344-2351. 
19. Cayla G, Hulot JS, O'Connor SA, et al. Clinical, 
angiographic, and genetic factors associated with early coronary 
stent thrombosis. JAMA 2011;306:1765-1774. 
20. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS 
Guidelines on myocardial revascularization: The Task Force on 
Myocardial Revascularization of the ESC and the EACTS 
Developed with the special contribution of the EAPCI. Eur 
Heart J 2014;35:2541-2619. 
21. Fukutomi T, Suzuki T, Popma JJ, et al. Early and late clinical 
outcomes following coronary perforation in patients undergoing 
percutaneous coronary intervention. Circ J 2002;66:349-356. 
22. Seshadri N, Whitlow PL, Acharya N, Houghtaling P, 
Blackstone EH, Ellis SG. Emergency coronary artery bypass 
surgery in the contemporary percutaneous coronary intervention 
era. Circulation 2002;106:2346-2350. 
23. Werner N, Bauer T, Hochadel M, et al. Incidence and clinical 
impact of stroke complicating PCI: results of the Euro heart 
survey percutaneous coronary interventions registry. Circ 
Cardiovasc Interv 2013;6:362-369. 
24. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial 
versus femoral access for coronary angiography or intervention 
and the impact on major bleeding and ischemic events: a 
systematic review and meta-analysis of randomized trials. Am 
Heart J 2009;157:132-140. 
25. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral 
access for coronary angiography and intervention in patients 
with acute coronary syndromes (RIVAL): a randomised, parallel 
group, multicentre trial. Lancet 2011;377:1409-1420. 
26. Ndrepepa G, Neumann FJ, Richardt G, et al. Prognostic value 
of access and non-access sites bleeding after percutaneous 
coronary intervention. Circ Cardiovasc Interv 2013;6:354-361. 
27. Pilgrim T, Kalesan B, Zanchin T, et al. Impact of atrial 
fibrillation on clinical outcomes among patients with coronary 
artery disease undergoing revascularisation with drug-eluting 
stents. EuroIntervention 2013;8:1061-1071. 
28. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after 
initiation of multiple antithrombotic drugs, including triple 
therapy, in atrial fibrillation patients following myocardial 
infarction and coronary intervention: a nationwide cohort study. 
Circulation 2012;126:1185-1193. 
29. Farouque HM, Tremmel JA, Raissi Shabari F, et al. Risk 
factors for the development of retroperitoneal hematoma after 
percutaneous coronary intervention in the era of glycoprotein 
IIb/IIIa inhibitors and vascular closure devices. J Am Coll 
Cardiol 2005;45:363-368. 
30. Feldman DN, Swaminathan RV, Kaltenbach LA, et al. 
Adoption of radial access and comparison of outcomes to 
femoral access in percutaneous coronary intervention: an 
updated report from the national cardiovascular data registry 
(2007-2012). Circulation 2013;127:2295-2306. 
31. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk 
score for prediction of contrast-induced nephropathy after 
percutaneous coronary intervention: development and initial 
validation. J Am Coll Cardiol 2004;44:1393-1399. 
32. Gurm HS, Seth M, Kooiman J, Share D. A novel tool for 
reliable and accurate prediction of renal complications in 
patients undergoing percutaneous coronary intervention. J Am 
Coll Cardiol 2013;61:2242-2248. 
33. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short-term high-
dose statin in preventing contrast-induced nephropathy: a meta-
analysis of seven randomized controlled trials. PLoS One 
2012;7:e34450. 
  
